Amgen’s (AMGN) treatment of systemic sclerosis, blinatumomab, was granted FDA orphan designation, according to a post to the agency’s site.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- What’s Included in AstraZeneca’s (AZN) ‘Historic’ Drug Discount Deal with Trump?
- AstraZeneca Stock (AZN) Flat despite Incoming Trump Pricing Deal, Virginia Plant Construction
- Trump Weekly: Generics to be excluded from pharma tariff plan
- GoodRx Stock (GDRX) Pops as U.S. Pharmacies Unite to Lobby for TrumpRx Participation
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports